Dave Hallett
About Dave Hallett
Dave Hallett serves as the Chief Operating Officer at Exscientia, bringing over 20 years of experience in the pharmaceutical and biotech sectors. He has a strong background in synthetic organic chemistry and has held various leadership roles in prominent companies, including Merck and Evotec.
Work at Exscientia
Dave Hallett has served as the Chief Operating Officer at Exscientia since 2020. In this role, he oversees operations in the company's Oxford, United Kingdom location. His responsibilities include managing the strategic direction of the organization and ensuring the successful execution of its drug discovery initiatives. Under his leadership, Exscientia focuses on integrating artificial intelligence into the drug development process.
Education and Expertise
Dave Hallett holds a BA in Natural Sciences from the University of Cambridge, completed from 1989 to 1992. He further pursued a PhD in Synthetic Organic Chemistry at the University of Manchester from 1992 to 1995. He also completed a Postdoctoral fellowship in Synthetic Organic Chemistry at The University of Texas at Austin from 1995 to 1996. His educational background supports his extensive expertise in medicinal chemistry, protein degradation therapeutic modalities, and the application of induced pluripotent stem cells (iPSCs) in drug discovery.
Background
Dave Hallett has over 20 years of experience in the pharmaceutical, contract research organization (CRO), and pharmatech sectors. He began his career as a Research Fellow at Merck, where he worked from 1996 to 2005. Following this, he held various executive roles at Evotec, including Executive Vice President of Chemistry and Executive Vice President of Alliance Management, from 2005 to 2019. His background includes significant involvement in the discovery and early development of small molecules.
Achievements
Throughout his career, Dave Hallett has contributed to advancements in medicinal chemistry and drug discovery. His work has focused on therapeutic areas such as neuroscience and pain. He has played a key role in integrating innovative approaches, including the use of iPSCs, into drug development processes. His leadership in various capacities has influenced the strategic direction of organizations within the pharmaceutical industry.